Journey Medical Corporation
DERM · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.99 | 0.02 | -0.09 | 0.41 |
| FCF Yield | -0.56% | -2.12% | 2.57% | -1.00% |
| EV / EBITDA | -100.53 | -65.60 | 26.76 | -142.64 |
| Quality | ||||
| ROIC | -6.55% | -7.12% | 4.75% | -9.05% |
| Gross Margin | 60.00% | 63.54% | 83.58% | 63.87% |
| Cash Conversion Ratio | 0.25 | 0.70 | 1.46 | 0.48 |
| Growth | ||||
| Revenue 3-Year CAGR | -9.41% | -2.83% | -3.50% | -8.66% |
| Free Cash Flow Growth | 66.74% | -227.28% | 292.31% | 77.65% |
| Safety | ||||
| Net Debt / EBITDA | -2.91 | -1.95 | 1.40 | 3.32 |
| Interest Coverage | -3.07 | -3.73 | 2.69 | -3.82 |
| Efficiency | ||||
| Inventory Turnover | 0.47 | 0.38 | 0.16 | 0.45 |
| Cash Conversion Cycle | 82.68 | 87.62 | 2.47 | 5.18 |